Fourth Quarter Highlights
Per Class B share(3): $1.02 adjusted basic earnings up 5.2%; $1.01 basic earnings up 359.1%; $0.54 goodwill impairment loss in 2023 basic earnings; currency translation negative $0.01 per share
Sales increased 9.0% on 6.8% organic growth, 1.4% acquisition growth and 0.8% positive currency translation
CCL, Checkpoint and Innovia posted organic sales growth of 5.4%, 13.3%, and 20.2%, respectively, partly offset by an organic decline for Avery of 2.0%
Operating income(1) improved 5.1%, with a 14.8% operating margin(1) down 50 bps
2024 Highlights
Per Class B share(3): $4.32 adjusted basic earnings up 14.9%; $4.73 basic earnings up 58.2%; $0.44 revaluation gain included in 2024 basic earnings and $0.54 goodwill impairment loss in 2023 basic earnings; currency translation negative $0.02 per share
Sales increased 9.0% on 6.1% organic growth, 2.3% acquisition growth and 0.6% positive currency translation
Operating income(1) improved 13.0%, with a 15.8% operating margin(1) up 60 bps
SHPE and Latino Donor Collaborative released a report with key facts showcasing a 60% increase for Hispanics in AI technical roles and rising STEM degrees for Latinos that help drive the U.S. economy forward.
Read More
Founder and Chief Executive Officer is Alan Sheriff, a former Vice Chairman of PNC Bank, a founder and former Co-CEO of Solebury Capital, and former Co-Head of Equity Capital Markets, Americas, Credit Suisse First Boston
Read MoreThis study, initiated yesterday, is one of five clinical efforts - three proof-of-concept (POC) investigator-initiated trials (IIT) and two Phase 2 studies - of crofelemer for the rare disease indications of SBS-IF and microvillus inclusion disease (MVID) in the US, EU, and/or Middle East/North Africa regions
Availability of first IIT proof-of-concept results potentially in H1 2025
Crofelemer, Jaguar's novel plant-based prescription drug, has been granted Orphan-Drug Designation by the FDA and the European Medicines Agency (EMA) for both SBS-IF and MVID
Read More
The global leader in dental imaging technologies will showcase the latest innovations added to its digital ecosystem - a suite of tools and software designed to connect the entire digital workflow from diagnosis to delivery.
Read More
New Mobile App to Offer Enhanced Features for Fans to Connect with Athletes, Celebrities, and Influencers, Opening Up New Revenue Streams for Fantribe and Tritent International
Read More
Blockchain Pioneer and Public Markets Executive Frank Yglesias Appointed CEO of Pineapple Express Cannabis Company (OTC: PNXP); Strategic Relocation to Atlanta Tech Hub Signals Transformation into Cannabis Authentication Technology Leader, Launching Revolutionary GROOVY Platform for Product Safety and Consumer Rewards.
Read More
Compassion Center is proud to partner with Psychedelic Science 2025 (PS2025), the premier global conference on psychedelic research and innovation hosted by MAPS. As an exhibitor, Compassion Center will highlight pioneering psychedelic-assisted programs, clinical research pathways, and strategic partnerships that advance mental health and integrative medicine. Visitors can explore breakthroughs in PTSD, addiction, and neurodegenerative disease treatments while engaging with leaders driving equitable access to transformative therapies.
Read More
Compassion Center proudly honors Dr. David Bearman for his pioneering work in medical cannabis, integrative healthcare, and patient advocacy. As Dr. Bearman retires, his legacy lives on through initiatives like CBCCERN, TeachOneServe10.org, and IntegrativeECS, reshaping care for millions. Amie Lindsay steps into a new leadership role, driving national expansion while preserving Compassion Center's mission: providing compassionate, evidence-based care and advancing integrative medicine across the U.S.
Read More
Compassion Center urges media outlets to report accurately on the DEA's active cannabis rescheduling hearings, emphasizing the importance of factual coverage during this pivotal regulatory process. Suggesting that the hearing is cancelled is a lie. Misinformation like this risks undermining patient access, public trust, and informed policymaking as the DEA evaluates moving cannabis to a Schedule III substance under the Controlled Substances Act (CSA). Compassion Center remains committed to providing expert insights and advocating for patie
Read More